Lipella Pharmaceuticals I... (LIPO)
2.96
-0.11 (-3.58%)
At close: Jan 15, 2025, 3:58 PM
2.94
-0.68%
After-hours Jan 15, 2025, 04:55 PM EST
undefined% (undefined)
| Bid | 2.94 |
| Market Cap | 3.58M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.29 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.1 |
| Volume | 30,920 |
| Avg. Volume (20D) | 146,702 |
| Open | 3.07 |
| Previous Close | 3.07 |
| Day's Range | 2.90 - 3.15 |
| 52-Week Range | 2.21 - 12.00 |
| Beta | undefined |
About LIPO
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Th...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2022
Employees 5
Stock Exchange NASDAQ
Ticker Symbol LIPO
Website https://www.lipella.com
Analyst Forecast
According to 1 analyst ratings, the average rating for LIPO stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 440.54% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-12.54%
Lipella Pharmaceuticals shares are trading lower. ...
Unlock content with
Pro Subscription
4 months ago ·
Source
+1.76%
Lipella Pharmaceuticals shares are trading lower. The company announced it will highlight clinical data on LP-20 at the 5th International Consultation on Interstitial Cystitis Japan in Kyoto, Japan.
